The Mayo Clinic PCI risk score identifies ACS patients at risk of in-hospital mortality, bleeding, contrast associated-AKI, and #stroke. #AHAJournals @antoniolandii @AndreaZito66 @mandeep_mayo @DFCapodanno @vlgmrc https://t.co/8Di72aTjXQ

External Validation of the Mayo Clinic PCI Risk Model. Use single pre-procedural model to calculate 4 outcomes: Mortality, AKI, Bleeding 🩸, and Stroke Thanks 🙏🏽 @vlgmrc @svrao @drdangiolillo @DFCapodanno Our research just got published in JAHA https://t.co/8YP3G1206K

Large thrombus burden management in a young patient with inferior STEMI and multivessel disease Part 1⃣🔗 https://t.co/nV5tTVA8De A 51-year-old patient presents with an inferior STEMI and multivessel disease. Angiography reveals a thrombotic sub-occlusion in the mid-RCA, and

And why de-escalate DAPT (i.e. switch to SAPT) if the patient is doing well without bleeding? Because no one has a major bleed until they have a major bleed! So be proactive and prevent an avoidable iatrogenic complication by discontinuing aspirin.

The story of AAS use on the top of anticoagulant is finally end. everyone will be now very conscious to avoid this combination, as it is unfortunately still used. https://t.co/JGF6yncQPX #ESCCongress 2025

Radial access for PCI: The good, the better, and the ugly. New trends from Europe and the US highlight the growing shift toward radial access, with promising outcomes in coronary procedures. A game-changer in PCI. Read more in #EHJ. https://t.co/cBhcKh5JF2 #cardiotwitter

Radial access for PCI: the good, the better, and the ugly @vlgmrc ➡️ https://t.co/dXPcjR62Jb Our editorial on a recent study from the NCDR CathPCI registry @SVRaoMD @rwyeh

💡 In PCI patients who had discontinued DAPT, P2Y12 inhibitor monotherapy was associated with lower MACCE compared with aspirin, without an increased risk of bleeding. Read more in @bmj_latest 🔗 https://t.co/O4puNRI4tM @vlgmrc @DanieleGiacoppo @PCRonline @TCTMD @theheartorg

Check out my latest article: Recurrent Events After PCI in High Bleeding Risk Patients: New Insights from the MASTER DAPT Trial https://t.co/0FccNJlieW via @LinkedIn

I was privileged to celebrate today @PCR the memory of Tiziana Zaro and dedicate her one sub-analysis of @masterdapt which we thought it was special and unique as she has been and will continue to be for us

Recurrent events after PCI in HBR patients #MASTERDAPT #euroPCR2025

Glad to be for my very first time to the @_anmco congress to tackle an increasingly recognized issue in practice: the decision-making process in elderly patients. @leonardodeluca @GianlucaCampo78 @MdMontalto

Here are 10 reasons NOT to routinely pre-treat NSTE-ACS patients with P2Y12 inhibitors

Featured Article: PIM acting as a weak reversible inhibitor seems to compete for the same binding site as PAM on the P2Y12 receptor @vlgmrc @antoniolandii https://t.co/MVjXGqvk90

Should the default duration of #DAPT after PCI in ACS be 12 months? Our great debate just published in @ehj_ed @vlgmrc @robebyrne @DLBHATTMD @CMichaelGibson @Borjaibanez1 @RosselloXavier @gabrielsteg @GreggWStone https://t.co/mpyOnmYOeO

Must apply!

Our call for consistency of evidence interpretation and guidelines recommendations on antiplatelet tx @CircAHA

💡Swinging Pendulum Between Risks and Benefits of Antiplatelet Agents: our call for consistency of future guideline recommendations just published in @CircAHA @vlgmrc https://t.co/3kK2bgUhGz

Double trouble: antithrombotic tx in #HBR patients with #diabetes undergoing PCI. Our latest insights from #MASTERDAPT ⬇️

"Hepatic T1 mapping has emerged as a novel imaging biomarker of the cardio-hepatic axis in STEMI, being associated with RV involvement and increased NT-proBNP" https://t.co/0kapWxAq5q Thanks to @AnnaGiuliaPavon for the leadership and to the whole Team! #whyCMR #CVimaging